Janux Therapeutics Inc (JANX) Live Share Price, Invest From India

Janux Therapeutics Inc Stock Performance

as on November 8, 2025 at 2:29 am IST

Day's Low
Day's High
$24.93
Day's Price Range
$29.14
$26.47
5.82%
Downside
10.09%
Upside
52 Week's Low
52 Week's High
$21.73
52-Week Price Range
$71.71
$26.47
17.91%
Downside
170.91%
Upside

Janux Therapeutics Inc share price movements today

Previous Close: $28.66
Open: $29.00
Volume: 1.7M
Day's Low - High: $24.93 - $29.14
52 Week Low - High: $21.73 - $71.71

Janux Therapeutics Inc Historical Returns

1 Month Return: + 9.42 %
3 Month Return: + 15.99 %
1 Year Return: -50.89 %
3 Year Return: + 54.76 %
5 Year Return: 0 %

Janux Therapeutics Inc Stock Fundamentals & Key Indicators

Check Janux Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

-2.2052

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-52.87

Industry PE ratio

8.355964912280701

PEG Ratio

EBITDA

-142.8M

Revenue (TTM)

439.0K

Profit Margin

0.00%

Return On Equity TTM

-12.82%

Janux Therapeutics Inc Stock Valuation

Track how Janux Therapeutics Inc P/E has moved over time to understand its valuation trends.

Janux Therapeutics Inc in the last 5 years

Overview
Trends

Lowest (-51.60x)

June 30, 2024

Today (-52.87x)

November 8, 2025

Industry (8.36x)

November 8, 2025

Highest (-5.24x)

September 30, 2021

LowHigh

Today’s Price to Earnings Ratio: -52.87x

Janux Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Janux Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Janux Therapeutics Inc	BUY	$1.7B	NA	-52.87	0.00%
Insmed Incorporated	BUY	$40.5B	482.44%	-16.34	-264.83%
Alnylam Pharmaceuticals, Inc.	BUY	$58.2B	238.64%	1420.94	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$105.6B	85.89%	29.33	31.35%
Regeneron Pharmaceuticals, Inc.	BUY	$68.0B	13.75%	15.51	32.13%

Stock Returns calculator for Janux Therapeutics Inc Stock including INR - Dollar returns

The Janux Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Janux Therapeutics Inc investment value today

Current value as on today

₹54,238

Returns

₹45,762

(-45.76%)

Returns from Janux Therapeutics Inc Stock

₹50,909 (-50.91%)

Dollar Returns*

₹5,147 (+5.15%)

Analyst Recommendation on Janux Therapeutics Inc Stock

Based on 15 analysts

BUY

93.33%

Buy

6.67%

Hold

0.00%

Sell

Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Janux Therapeutics Inc. Average target price of $78.59

Janux Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Janux Therapeutics Inc.

What analysts predicted

66.32%UPSIDE

Target Price

$78.59

Current Price

$26.47

Analyzed by

15 Analysts

Target

$78.59

Janux Therapeutics Inc target price $78.59, a slight upside of 66.32% compared to current price of $26.47. According to 15 analysts rating.

Janux Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Janux Therapeutics Inc Stock has increased by 205% in the last 30 days, reflecting an upward trend in search activity.

Time period: October 10, 2025 to November 9, 2025

Change:205% versus previous 30 day period

Janux Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	2	1	2	2	1	8	0	-8	-	-
Gross Profit	1	0	2	1	0	8	0	-9	0	0
Operating Income	-20	-20	-15	-16	-20	-13	-35	-29	-34	-45
EBITDA	-19	-20	-15	-15	-19	-13	-35	-28	-34	-45
Interest Expense	3	-	-	3	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-17	-17	-11	-11	-14	-5	-28	-20	-23	-33
Income Tax Expense	0	0	0	0	0	-	-	-	-	-
Net Income	-17	-17	-11	-11	-14	-5	-28	-20	-23	-33
Net Profit Margin	-852.49%	-1656.39%	-459.59%	-477.77%	-1178.91%	-66.98%	-6391.57%	237.50%	0.00%	0.00%

Janux Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	0	3	8	8	10
Gross Profit	0	0	3	8	6	8
Operating Income	-3	-4	-32	-67	-72	-98
EBITDA	-3	-6	-32	-66	-71	-98
Interest Expense	0	0	0	4	-	-
Depreciation	0	0	0	0	1	2
Income Before Tax	-4	-6	-32	-63	-58	-68
Income Tax Expense	0	-1	0	-8	1	-
Net Income	-4	-5	-32	-54	-58	-68
Net Profit Margin	0.00%	-1382.89%	-895.22%	-628.82%	-721.18%	-651.62%

Janux Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-17	-11	-11	-14	-5	-28	-20	-23	-33
Operating Cash Flow	-15	-11	-9	-14	-10	-2	-16	-17	-23
Investing Cash Flow	17	-61	11	-113	-190	12	33	-340	1
Financing Cash Flow	0	56	0	322	2	1	386	0	0
Change in Cash	3	-16	2	193	-198	12	403	-356	-21

Janux Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-6	-32	-63	-58	-68
Operating Cash Flow	-4	-16	-42	-50	-43
Investing Cash Flow	-340	-340	58	-41	-258
Financing Cash Flow	11	386	0	59	713
Change in Cash	7	28	15	-32	411

Global Institutional Holdings in Janux Therapeutics Inc

Funds	Holdings
RA Capital Management, LLC	18.62%
FMR Inc	14.79%
HHG PLC	7.42%
BlackRock Inc	5.66%
Paradigm Biocapital Advisors LP	4.86%

See all

Insights on Janux Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, JANX stock has moved up by 18.4%
NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 152.5% return, outperforming this stock by 199.3%
NO EFFECT
Against Peers
In the last 3 years, Insmed Incorporated has given 897.2% return, outperforming this stock by 829.7%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 8.89M → -8.51M (in $), with an average decrease of 1067.0% per quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, -20.21M → -33.85M (in $), with an average decrease of 30.2% per quarter

About Janux Therapeutics Inc

janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr

Organisation	Janux Therapeutics Inc
Headquarters	10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
Industry	Services
CEO	Dr. David Alan Campbell Ph.D.
E-voting on shares	Click here to vote

Key Management of Janux Therapeutics Inc

Name	Title
Dr. Thomas Diraimondo Ph.D.	Chief Scientific Officer
Mr. Matt Whitmire	Vice President of Finance
Ms. Maria Dobek	Principal Accounting Officer & VP of Accounting
Mr. Charles M. Winter	Chief Technical Officer
Dr. David Alan Campbell Ph.D.	President, CEO & Director
Mr. James Pennington	General Counsel & Corporate Secretary
Ms. Janeen Doyle	Chief Corporate & Business Development Officer
Mr. Andy Hollman Meyer	Chief Business Officer
Dr. Zachariah McIver D.O., Ph.D.	Chief Medical Officer

FAQs

What is Janux Therapeutics Inc share price today?

Janux Therapeutics Inc share price today is $26.47 as on November 8, 2025 at 2:29 am IST at the close of the market. Janux Therapeutics Inc share today touched a day high of $29.14 and a low of $24.93.

What is the 52 week high and 52 week low for Janux Therapeutics Inc share?

Janux Therapeutics Inc share touched a 52 week high of $71.71 on December 5, 2024 and a 52 week low of $21.73 on September 25, 2025. Janux Therapeutics Inc stock price today i.e. November 8, 2025 at 2:29 am IST is closed at $26.47,which is 63.09% down from its 52 week high and 21.81% up from its 52 week low.

What is Janux Therapeutics Inc's market capitalisation today?

Janux Therapeutics Inc market capitalisation is $0.00T as on November 8, 2025 at 2:29 am IST.

How to invest in Janux Therapeutics Inc Stock (JANX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Janux Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Janux Therapeutics Inc Shares that will get you 0.0567 shares as per Janux Therapeutics Inc share price of $26.47 per share as on November 8, 2025 at 2:29 am IST.

What is the minimum amount required to buy Janux Therapeutics Inc Stock (JANX) from India?

Indian investors can start investing in Janux Therapeutics Inc (JANX) shares with as little as ₹88.66 or $1 (as of November 9, 2025 at 11:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹886.60 in Janux Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on November 9, 2025 at 11:42 am IST). Based on Janux Therapeutics Inc share’s latest price of $26.47 as on November 8, 2025 at 2:29 am IST, you will get 0.3778 shares of Janux Therapeutics Inc. Learn more about fractional shares .